RBC Capital says the data from Crinetics (CRNX) demonstrate the potential arrival of another congenital adrenal hyperplasia agent down the line. The firm continues to expect gradual market uptake for Neurocrine’s (NBIX) crinecerfont. RBC’s previous feedback from both patients and physicians have highlighted potential challenges for crinecerfont market uptake anyway, the analyst tells investors in a research note. The firm keeps a Sector Perform rating on Neurocrine.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine presents baseline data of CAH program
- Neurocrine initiated with an Outperform at Evercore ISI
- Neurocrine presents CAHtalyst adult study baseline characteristics, data
- Neurocrine announces initiation of Phase 1 study evaluating NBI-1076986
- Neurocrine initiates Phase 1 clinical study of NBI-1117567 in healthy adults